Small-cap growth stocks offer the perfect arena for stock pickers. Read More
Benjamin Shepherd is a recognized exchange-traded fund (ETF), mutual fund and stock expert with an extensive background analyzing time-tested funds, including their managers and strategies. Ben looks for investments that have proven themselves in both bull and bear markets. Ben also specializes in covering emerging markets, pinpointing the most dynamic investments in developing nations for market-beating growth.
Ben is an analyst for Global Income Edge and regularly contributes to Personal Finance, Investing Daily’s flagship product.
Analyst Articles
Add a diversified allocation to commodities. Read More
This mutual fund buys large-cap stocks at a discount. Read More
Our stock-screening series continues with a guide to value screens. Read More
Online stock screeners are versatile investment tools, and every investor should use them to generate investment ideas that merit further research. But, before you use a stock screener, you must decide how to use the results of your screen. Some investors build very broad screens to be used simply for… Read More
Offensive Strategy While a defensive approach to equities was the best strategy last year, our view is that continued economic improvement in the US, a quieting of the European sovereign-debt crisis and further growth in emerging markets justifies a more offensive stance. For 2012, our favorite sectors are industrials, technology… Read More
Corporate bonds offer compelling yields relative to high-priced Treasuries. And our latest play on corporate debt offers investors additional yield by slightly extending the duration of its portfolio. Read More
As the US economy strengthens, it’s time for investors to consider adding greater risk to their portfolios. To that end, we highlight the best ETFs among our three favored sectors. Read More
It could be difficult for investors to capitalize on the latest advance in gene sequencing. But we’ve found one ETF that provides broad exposure to this disruptive technology. Read More
It could be difficult for investors to capitalize on the latest advance in gene sequencing. But we’ve found one ETF that provides broad exposure to this disruptive technology. Read More